New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
12:00 EDTAGIOAgios Pharmaceuticals rises 26.1%
Agios Pharmaceuticals is up 26.1%, or $9.24, to $44.71
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
08:23 EDTAGIOAgios Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
June 24, 2015
09:14 EDTAGIOAgios Pharmaceuticals management to meet with Leerink
Meeting to be held in Boston on June 29 hosted by Leerink.
07:32 EDTAGIOAgios Pharmaceuticals announces first patient dosed with AG-881 in Phase 1 study
Agios Pharmaceuticals announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of single agent AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood-brain barrier and inhibit isocitrate dehydrogenase-1 and IDH2 mutations in cancer models. The purpose of the Phase 1 multi-center, open-label study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors. AG-881 will be administered continuously as a single agent dosed orally in a 28-day cycle. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending oral doses of AG-881 to determine the maximum tolerated dose and/or the recommended Phase 2 dose based on safety and tolerability. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability and clinical activity of the recommended Phase 2 dose.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use